The pharmaceutical industry is undergoing a significant transformation driven by numerous factors. These include the need for greater R&D efficiency, reducing expenditure for in-market assets to refresh the pipeline and adapting to a more diversified knowledge exchange ecosystem — all calling for greater efficiency. Within this transformation, the role of medical affairs teams and the challenges these teams face are changing. Medical affairs teams are increasingly challenged to do more with less, managing a growing number of assets with shrinking budgets and tighter timelines.
In this eBook you’ll learn about:
Jump to a slide with the slide dots.
China is emerging as a global oncology innovation hub, reshaping clinical development, dealmaking, and advanced therapy sourcing worldwide.
Read moreAI is rapidly transforming how healthcare professionals discover, interpret, and trust scientific evidence. Tools such as ChatGPT, OpenEvidence, and G
Read moreDiscover how patient-centric insights boost HCP engagement and commercial impact in this 30-minute session with experts from Research Partnership and
Read more